News | Proton Therapy | April 04, 2017

S250i with Hyperscan allows hyper-fast and ultra-sharp pencil beam scanning

Mevion, S250i proton therapy system, Hyperscan pencil beam scanning, installation, MedStar Georgetown University Hospital

April 4, 2017 — Mevion Medical Systems announced the installation of the first Mevion S250i proton therapy system with Hyperscan pencil beam scanning at MedStar Georgetown University Hospital in Washington, D.C. This technology will allow MedStar Georgetown to deliver enhanced intensity modulated proton therapy (IMPT) by combining fast energy modulation with sharp lateral penumbra, improving the treatment options available to cancer patients.

This is the first installation of Hyperscan with Adaptive Aperture, Mevion’s novel proton multi-leaf collimator. The installation at MedStar Georgetown will be followed by a Mevion S250i installation at Zuidoost Nederland Protonen Therapie Centrum, co-located at the Maastricht Clinic, in the Netherlands, and at the Ackerman Cancer Center in Jacksonville, Fla., the second unit installed at the private, physician-run center.

The Adaptive Aperture is a proprietary low-profile micro-multi-leaf collimator system designed specifically for Hyperscan pencil beam scanning. It eliminates the need for manual apertures and adjustments because its layer-by-layer beam collimation achieves one to three millimeter collimated effective spot sizes for all energies. Hyperscan with Adaptive Aperture is capable of scanning a typical lung tumor in less than two seconds – eliminating many of the challenges caused by patient motion that other pencil beam scanning systems encounter.

Proton therapy provides targeted radiation treatment for many types of cancer, significantly reducing the dose of radiation to healthy tissue by as much as a factor of three, while still maintaining high conformance to the treatment target.

For more information: www.mevion.com


Related Content

News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
Feature | ASTRO | By Christine Book

September 26, 2023 — Ahead of the 65th American Society for Radiation Oncology Annual Meeting, ASTRO 2023, ITN’s ...

Time September 26, 2023
arrow
News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
Feature | Radiation Oncology

The radiation oncology community lost a leader this past summer, with the passing of Jay Loeffler, MD, FACR, FASTRO. He ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | Radiation Oncology

September 6, 2023 — Nina D’Abreo, MD, has been named as chief of the Division of Hematology and Medical Oncology at NYU ...

Time September 06, 2023
arrow
News | Radiation Oncology

August 30, 2023 — Elekta and the IAEA have signed a partnership agreement to jointly pursue common interests, including ...

Time August 30, 2023
arrow
News | Radiation Therapy

August 30, 2023 — A published study by researchers at the University of Cincinnati Cancer Center and Cincinnati Children ...

Time August 30, 2023
arrow
News | Radiopharmaceuticals and Tracers

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that ...

Time August 28, 2023
arrow
Subscribe Now